Status:
UNKNOWN
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Solid Tumor
Lymphoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment. Enhancer of zeste homolog 2 (EZH2) as a epigenetic target for ...
Detailed Description
Immune checkpoint blockade has led to great strides in the management of various cancers, however, durable response could be seen in approximately 20% of treated patients with most solid malignancies....
Eligibility Criteria
Inclusion
- 1\. Age from 18 to 70 years with estimated life expectancy \>3 months.
- 2\. Histopathological confirmed locally advanced or metastatic systematically pretreated epidermal growth factor receptor (EGFR) / anaplastic lymphoma kinase (ALK) / c-ros oncogene 1 receptor kinase (ROS1) /BRAF negative non-small cell lung cancer (adenocarcinoma or squamous cell carcinoma), pancreatic adenocarcinoma, cholangiocarcinoma, gastrointestinal adenocarcinoma, triple-negative breast cancer and relapsed/refractory B-cell lymphoma (All enrolled subjects with above solid carcinoma are required to have received at least first-line systematic therapy and subjects with R/R B-cell lymphoma need a history of at least two lines of previous treatment; For solid carcinoma subjects enrolled in phase Ⅱ period, their previous treatment lines are limited to no more than four lines; Besides previously treated subjects, subjects with initially diagnosed pancreatic adenocarcinoma or cholangiocarcinoma are also eligible for enrollment in phase Ⅱ period).
- 3\. Have at least one measurable target lesion, determined by the site study team based on RECIST 1.1 and immune related RECIST.
- 4\. Fresh tumor samples or formalin-fixed paraffin embedded tumor archival samples within 3 months are necessary; Fresh tumor samples are preferred. Subjects are willing to accept tumor re-biopsy in the process of this study.
- 5\. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to \<= grade 1 toxicity.
- 6\. Have an Eastern Cooperative Oncology Group performance status (ECOG) of 0 or 1 at the time of enrollment.
- 7\. Have adequate organ function, as defined in the table below, which should be confirmed within 2 weeks prior to the first dose of study drugs.
- Leukocytes greater than or equal to 3.0 ×10\^9/L.
- Absolute neutrophil counts greater than or equal to 1.0 ×10\^9/L.
- Platelets greater than or equal to 100 ×10\^9/L.
- Hemoglobin greater than or equal to 90 g/L.
- Total bilirubin less than or equal to 2 x ULN.
- Serum albumin should be no less than 30 g/L.
- Alanine aminotransferase or Aspartate aminotransferase less than 2 x Upper Limit of Normal (ULN).
- Measured creatinine clearance ≥ 60 mL per min.
- 8\. Previous treatment with anti-PD-1/PD-L1 antibodies or cytotoxic T lymphocyte associated antigen 4 (CTLA-4) inhibitors are allowed.
- 9\. Ability to understand and sign a written informed consent document.
- Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and up to 90 days after the last dose of the drug.
Exclusion
- 1\. Active, known or suspected autoimmune diseases.
- 2\. Known brain metastases or active central nervous system (CNS). Subjects with CNS metastases who were treated with radiotherapy for at least 3 months prior to enrollment, have no central nervous symptoms and are off corticosteroids, are eligible for enrollment, but require a brain MRI screening.
- 3\. Subjects are being treated with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
- 4\. History of severe hypersensitive reactions to other monoclonal antibodies.
- 5\. History of allergy or intolerance to study drug components.
- 6\. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- 7\. History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function.
- 8\. Uncontrolled intercurrent illness, including ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
- 9\. History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- 10\. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented.
- 11\. Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\].
- 12\. Vaccination within 30 days of study enrollment.
- 13\. Active bleeding or known hemorrhagic tendency.
- 14\. Subjects with unhealed surgical wounds for more than 30 days.
- 15\. Being participating any other trials or withdraw within 4 weeks.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04407741
Start Date
September 1 2020
End Date
December 1 2025
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Biotherapeutic, Chinese PLA General Hospital
Beijing, China